Lipocine Inc（LPCN）の株式分析LPCNLipocine Inc

Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to enable effective oral delivery of therapeutics. The Company’s clinical development candidates include: LPCN 1154, oral brexanolone, for the treatment of postpartum depression, LPCN 2101, for the treatment of epilepsy, LPCN 2203, an oral candidate targeted for the management of essential tremor, LPCN 2401, an oral proprietary anabolic androgen receptor agonist for improved body composition in obesity management, and LPCN 1148, for the management of decompensated cirrhosis. It is also developing LPCN 1107, for the prevention of preterm birth, LPCN 1154, for rapid relief of postpartum depression, and LPCN 1144, for the treatment of metabolic dysfunction-associated steatohepatitis. Its product candidate, TLANDO, is a novel oral prodrug of testosterone containing testosterone undecanoate developed by the Company. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Lipocine Inc is not a good buy right now due to significant risks and uncertainty surrounding its future. The stock price is currently at $2.17, which is down 72.88% year-to-date. The forward P/E ratio is 5.64, indicating potential undervaluation, but the recent Phase 3 trial failure has led to a negative sentiment that could hinder recovery. The main risk is the company's ongoing losses, with a net income of -$2,622,595 reported in Q2 2026, which raises concerns about its financial stability.

4 analysts cover LPCN: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.88.